UY28171A1 - Vacunas caninas contra bordetella bronchiseptica - Google Patents

Vacunas caninas contra bordetella bronchiseptica

Info

Publication number
UY28171A1
UY28171A1 UY28171A UY28171A UY28171A1 UY 28171 A1 UY28171 A1 UY 28171A1 UY 28171 A UY28171 A UY 28171A UY 28171 A UY28171 A UY 28171A UY 28171 A1 UY28171 A1 UY 28171A1
Authority
UY
Uruguay
Prior art keywords
canine
caused
bordetella bronchiseptica
leptospira
vaccines
Prior art date
Application number
UY28171A
Other languages
English (en)
Inventor
Paul Joseph Dominowski
Joseph Claude Frantz
Richard Lee Krebs
Shelly Lynn Shields
Robert Greg Sorensen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28171A1 publication Critical patent/UY28171A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Este invento se refiere a vacunas y métodos para proteger a perros frente a una enfermedad causada por Bordetella bronchiseptica. Este invento se refiere también a vacunas en combinación y a métodos para proteger a perros frente a una enfermedad o un trastorno, que se ha causado por patógenos caninos, por ejemplo, una traqueobronquitis infecciosa causada por Bordetella bronchiseptica, un moquillo canino causado por virus del moquillo canino (CD) , una hepatitis canina infecciosa (ICH) cuasada por adenovirus caninos del tipo 1 (CAV-1), una enfermedad respiratoria causada por adenovirus caninos del tipo 2 (CAV-2), una parainflenza canina causada por virus de la parainfluenza canina (CPI), una enteritis causada por coronavirus caninos (CCV) y parvovirus caninos (CPV), y una leptospirosis causada por Leptospira bratislava, Leptospiran canicola, Leptospira grippotyphosa, Leptospira icterhaemorrhagiae o Leptospira pomona. Las vacunas del presente invento incluyen un antígeno p68 procedente de Bordetella bronchiseptica.
UY28171A 2003-01-29 2004-01-28 Vacunas caninas contra bordetella bronchiseptica UY28171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44341803P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
UY28171A1 true UY28171A1 (es) 2004-08-31

Family

ID=32825327

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28171A UY28171A1 (es) 2003-01-29 2004-01-28 Vacunas caninas contra bordetella bronchiseptica

Country Status (21)

Country Link
US (2) US20040185062A1 (es)
EP (1) EP1592444B1 (es)
JP (3) JP2006515024A (es)
KR (1) KR20050103215A (es)
CN (1) CN1835767A (es)
AR (1) AR042935A1 (es)
AT (1) ATE395077T1 (es)
AU (1) AU2004208556B2 (es)
BR (1) BRPI0407032A (es)
CA (1) CA2513352C (es)
DE (1) DE602004013723D1 (es)
ES (1) ES2303046T3 (es)
HR (1) HRP20050660A2 (es)
MX (1) MXPA05008051A (es)
NO (1) NO20053734L (es)
PL (1) PL378001A1 (es)
RU (1) RU2005124130A (es)
TW (1) TW200505476A (es)
UY (1) UY28171A1 (es)
WO (1) WO2004067031A1 (es)
ZA (1) ZA200506073B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
JP5393978B2 (ja) * 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
EP1871410A2 (en) * 2005-04-07 2008-01-02 Pharmacia & Upjohn Company LLC Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
BRPI0603490B1 (pt) * 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais Vacina recombinante contra a leishmaniose visceral canina
EP2377550B1 (en) * 2006-09-11 2015-03-04 Zoetis P LLC Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
NZ577855A (en) 2006-12-27 2012-07-27 Pfizer Prod Inc Vaccination schedule to prevent canine disease
PL2134742T3 (pl) * 2007-02-27 2012-10-31 Zoetis Services Llc Kompozycje immunogenne do leczenia i profilaktyki zakażeń zwierząt
ES2728949T3 (es) * 2008-06-27 2019-10-29 Zoetis Services Llc Composiciones adyuvantes novedosas
BR112012008861A2 (pt) * 2009-10-14 2019-09-24 Univ Oklahoma State parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 de parvovírus purificada, vetor de expressão, e método para exterminar células tumorais em um mamífero.
US9381241B2 (en) * 2010-09-28 2016-07-05 Kyoritsu Seiyaku Corporation Mucosal adjuvant composition
CA2821422C (en) * 2010-12-22 2024-01-02 Intervet International B.V. Vaccines comprising live aro mutant bordetella bronchiseptica
RU2553222C2 (ru) * 2011-02-04 2015-06-10 ЗОИТИС ЭлЭлСи Композиции для лечения и предупреждения комплекса респираторных заболеваний собак
EP3858381A1 (en) * 2011-02-04 2021-08-04 Zoetis Services LLC Immunogenic bordetella bronchiseptica compositions
JP6313752B2 (ja) 2012-05-31 2018-04-18 ゾエティス・エルエルシー Ｂ．ブロンキセプチカ（Ｂ．Ｂｒｏｎｃｈｉｓｅｐｔｉｃａ）感染から保護するためのイヌ呼吸器コロナウイルスでのワクチン接種
CZ307883B6 (cs) * 2013-01-29 2019-07-24 Bioveta, A.S. Multivalentní vakcína k imunoprofylaxi infekčních onemocnění psů
AU2014321369B2 (en) 2013-09-19 2020-04-16 Zoetis Services Llc Oil-based adjuvants
WO2016115456A1 (en) 2015-01-16 2016-07-21 Zoetis Services Llc Foot-and-mouth disease vaccine
CN107249629A (zh) * 2015-02-26 2017-10-13 生控基因疫苗股份有限公司 包含免疫原性蛋白质及组合佐剂并用以诱发抗原特异性t细胞反应的疫苗组合物
CN106399260B (zh) * 2015-07-31 2021-03-02 北京大北农科技集团股份有限公司动物医学研究中心 一种犬瘟热、细小病毒病二联活疫苗及其制备方法
TW202206098A (zh) * 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950512A (en) * 1972-07-25 1976-04-13 Pitman-Moore, Inc. Animal vaccines
GB2048669A (en) * 1979-05-18 1980-12-17 Moskov Nii Virusnykh Preparato Canine distemper vaccines
US4567043A (en) * 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
GB8502399D0 (en) * 1985-01-31 1985-03-06 Akzo Nv Canine parvovirus vaccines
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DK0465204T3 (da) * 1990-07-06 2000-10-09 American Home Prod Vaccine mod Lyme sygdom
GB9106568D0 (en) * 1991-03-27 1991-05-15 Wellcome Found Recombinant antigen
ZA927037B (en) * 1991-09-30 1993-03-29 Akzo Nv Respiratory disease vaccine for cats.
JP2521226B2 (ja) * 1993-01-28 1996-08-07 株式会社微生物化学研究所 犬用多種混合ワクチン
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines

Also Published As

Publication number Publication date
CN1835767A (zh) 2006-09-20
HRP20050660A2 (en) 2006-02-28
NO20053734D0 (no) 2005-08-03
EP1592444B1 (en) 2008-05-14
MXPA05008051A (es) 2005-09-21
US20040185062A1 (en) 2004-09-23
ZA200506073B (en) 2006-05-31
TW200505476A (en) 2005-02-16
CA2513352C (en) 2010-10-12
EP1592444A1 (en) 2005-11-09
DE602004013723D1 (de) 2008-06-26
JP2007161718A (ja) 2007-06-28
KR20050103215A (ko) 2005-10-27
ATE395077T1 (de) 2008-05-15
AU2004208556A1 (en) 2004-08-12
CA2513352A1 (en) 2004-08-12
JP2011137017A (ja) 2011-07-14
US7736658B2 (en) 2010-06-15
PL378001A1 (pl) 2006-02-20
JP2006515024A (ja) 2006-05-18
RU2005124130A (ru) 2006-01-20
WO2004067031A1 (en) 2004-08-12
AU2004208556B2 (en) 2009-06-04
JP5319882B2 (ja) 2013-10-16
AR042935A1 (es) 2005-07-06
ES2303046T3 (es) 2008-08-01
NO20053734L (no) 2005-10-26
BRPI0407032A (pt) 2006-01-17
US20080226670A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
UY28171A1 (es) Vacunas caninas contra bordetella bronchiseptica
CY1114897T1 (el) Πολυδυναμα εμβολια για σκυλους εναντια στην λεπτοσπειρα bratislava και αλλα παθογονα
PE20040420A1 (es) Vacunas para enfermedades reproductivas del ganado
AR064530A1 (es) Procedimientos para la administracion de vacunas
RU2006140984A (ru) Вакцина против пародонтоза
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
AR070675A1 (es) Bacterinas tratadas termicamente y vacunas de emulsion preparadas a partir de tales bacterinas tratadas termicamente
AR043892A1 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
BRPI0407436A (pt) Composições adesivas para dentaduras, bem como método para a obtenção de efeito antiplaca
UA110505C2 (ru) Імуногенні композиції bordetella bronchiseptica
TH71070A (th) วัคซีนสุนัขต้าน Bordetella bronchiseptica
PT784486E (pt) Inerleucina-12 como um adjuvante para vacinas contra paramyxoviridae
WO2008106393A3 (en) Immunogenic compositions and methods for treating and preventing animal infections
RU2012143152A (ru) Способ защиты от заболеваний, вызываемых вторичными патогенами
CO5690616A2 (es) Vacunas para enfermedades reproductoras del ganado
MX2013009013A (es) Composiciones para el complejo de enfermedad respiratoria canina.
Casal How have vaccines changed the incidence of infectious diseases?
Ayar et al. Effects of adhesive drying methods to reduce aerosol generation during resin bonding on enamel bond strength
DOP2003000699A (es) Vacunas para enfermedades reproductoras del ganado

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160620